Elevated Capital Advisors LLC Has $704,000 Stake in Eli Lilly and Company $LLY

Elevated Capital Advisors LLC reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 42.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 765 shares of the company’s stock after selling 559 shares during the period. Elevated Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $704,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Accredited Investors Inc. boosted its holdings in shares of Eli Lilly and Company by 6.6% during the 1st quarter. Accredited Investors Inc. now owns 4,250 shares of the company’s stock worth $3,909,000 after buying an additional 264 shares during the period. Graetz Wealth LLC bought a new position in Eli Lilly and Company in the 1st quarter worth $231,000. Roman Butler Fullerton & Co. raised its holdings in Eli Lilly and Company by 0.5% in the 1st quarter. Roman Butler Fullerton & Co. now owns 7,341 shares of the company’s stock worth $6,998,000 after acquiring an additional 33 shares during the period. Range Financial Group LLC lifted its position in Eli Lilly and Company by 2.8% during the 1st quarter. Range Financial Group LLC now owns 5,266 shares of the company’s stock worth $4,843,000 after acquiring an additional 142 shares during the last quarter. Finally, Peterson Wealth Services lifted its position in Eli Lilly and Company by 6.5% during the 1st quarter. Peterson Wealth Services now owns 4,902 shares of the company’s stock worth $4,508,000 after acquiring an additional 298 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bank of America raised its price target on Eli Lilly to $1,334 from $1,251 and kept a buy rating, signaling confidence that the company still has meaningful upside after its recent run. Benzinga article
• Positive Sentiment: Lilly announced that its Phase 2 neuropathic pain trial reached completion, adding another potentially valuable pipeline asset beyond its blockbuster GLP-1 franchise. TipRanks article
• Positive Sentiment: News flow highlighting record GLP-1 adoption and accelerating sales remains supportive, since Lilly’s obesity and diabetes drugs continue to be the main driver of earnings momentum. Motley Fool article
• Positive Sentiment: Additional analyst commentary has been upbeat, with other firms also lifting targets and framing Lilly as one of the strongest growth names in healthcare. TheStreet article
• Neutral Sentiment: Institutional buying and “best mutual funds” lists suggest Lilly remains a favored large-cap healthcare holding, but this is more a sentiment indicator than a direct catalyst. Yahoo Finance article
• Negative Sentiment: Tampa General’s lawsuit over allegedly pulled 340B discounts adds legal and reimbursement risk, which could create some investor caution around Lilly’s pricing and hospital-channel relationships. Healthcare Finance News article

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $1,189.06 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The company has a market cap of $1.12 trillion, a PE ratio of 42.24, a price-to-earnings-growth ratio of 1.51 and a beta of 0.51. The firm has a fifty day moving average price of $1,098.66 and a two-hundred day moving average price of $1,033.53. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business’s revenue was up 55.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 35.81 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LLY. Royal Bank Of Canada raised their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research report on Wednesday. Wolfe Research reissued an “outperform” rating and set a $1,350.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, May 21st. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Tuesday. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Finally, UBS Group set a $1,370.00 target price on Eli Lilly and Company in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,263.41.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.